Advanced search
Publication Cover
Future Medicinal Chemistry Volume 11, 2019 - Issue 10
Submit an article Journal homepage
180
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Discovery of Novel 1,2,4-triazolo-1,2,4-triazines with Thiomethylpyridine Hinge Binders as Potent c-Met Kinase Inhibitors

Sakineh Dadashpour1 Department of Medicinal ChemistryFaculty of PharmacyMazandaran University of Medical SciencesSariIran;2 Student Research CommitteeMazandaran University of Medical SciencesSariIran
,
Tuba Tüylü Küçükkılınç3 Department of BiochemistryFaculty of PharmacyHacettepe UniversitySihhiyeAnkara06100Turkey
,
Beyza Ayazgök3 Department of BiochemistryFaculty of PharmacyHacettepe UniversitySihhiyeAnkara06100Turkey
,
Seyed Jalal Hosseinimehr4 Department of RadiopharmacyFaculty of PharmacyMazandaran University of Medical SciencesSariIran
,
Ann M Chippindale5 Department of ChemistryUniversity of ReadingWhiteknightsReadingBerksRG6 6ADUK
,
Alireza Foroumadi6 Department of Medicinal ChemistryFaculty of Pharmacy and The Institute of Pharmaceutical Sciences (TIPS)Tehran University of Medical SciencesTehranIran
&
Hamid Irannejad1 Department of Medicinal ChemistryFaculty of PharmacyMazandaran University of Medical SciencesSariIranCorrespondence[email protected]
 show all
Pages 1119-1136 | Received 22 Aug 2018, Accepted 14 Feb 2019, Published online: 08 Jul 2019

References

  • Trusolino L , BertottiA, ComoglioPM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol.11(12), 834–848 (2010).
  • Birchmeier C , BirchmeierW, GherardiE, Vande WoudeGF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol.4(12), 915–925 (2003).
  • Cui JJ . Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J. Med. Chem.57(11), 4427–4453 (2014).
  • Ma YC , SunGQ, ChenDQet al. Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors. J. Med. Chem.58(5), 2513–2529 (2015).
  • Albrecht BK , HarmangeJC, BauerDet al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem.51(10), 2879–2882 (2008).
  • Buchanan SG , HendleJ, LeePSet al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther.8(12), 3181–3190 (2009).
  • Chen F , WangY, AiJet al. O-linked triazolotriazines: potent and selective c-Met inhibitors. ChemMedChem7(7), 1276–1285 (2012).
  • Cui JJ , MctigueM, NambuMet al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J. Med. Chem.55(18), 8091–8109 (2012).
  • Rigaku . Xcalibur/SuperNova CCD System (formerly Oxford Diffraction), CrysAlisPro Software System, Version 1.171.36.21. Rigaku Ltd., Tokyo, Japan (2012). www.rigaku.com/en/products/smc/crysalis
  • Palatinus L , ChapuisG. SUPERFLIP – a computer program for the solution of crystal structures by charge flipping in arbitrary dimensions. J. Appl. Crystallogr.40, 786–790 (2007).
  • Betteridge PW , CarruthersJR, CooperRI, ProutK, WatkinDJ. CRYSTALS version 12: software for guided crystal structure analysis. J. Appl. Crystallogr.36, 1487–1487 (2003).
  • Macrae CF , BrunoIJ, ChisholmJAet al. Mercury CSD 2.0 – new features for the visualization and investigation of crystal structures. J. Appl. Crystallogr.41, 466–470 (2008).
  • Jia H , DaiGX, WengJYet al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J. Med. Chem.57(18), 7577–7589 (2014).
  • Liao WK , XuC, JiXHet al. Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors. Eur. J. Med. Chem.87, 508–518 (2014).
  • Fujita H , MiyaderaK, KatoMet al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol. Cancer Ther.12(12), 2685–2696 (2013).
  • Antoine M , GerlachM, GuntherEet al. A convenient synthesis of novel 2,8-disubstituted pyrido[3,4-b]pyrazines possessing biological activity. Synthesis-Stuttgart44(1), 69–82 (2012).
  • Zhan ZS , PengX, LiuQFet al. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b] [1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. Eur. J. Med. Chem.116, 239–251 (2016).
  • Doyle KJ , JonesGP, RussellMGN, BrucknerS, MacRitchieJA, PeachJ. US20090318429A1 (2009).
  • Irannejad H , KebriaieezadehA, ZarghiAet al. Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors. Bioorgan. Med. Chem.22(2), 865–873 (2014).
  • El-Sayed WA , NassarIF, Abdel-RahmanAaH. Synthesis and antitumor activity of new 1,2,4-triazine and [1,2,4]triazolo[4,3-b][1,2,4]triazine derivatives and their thioglycoside and acyclic C-nucleoside analogs. J. Heterocyclic Chem.48(1), 135–143 (2011).
  • Dadashpour S , KucukkilincTT, TanOU, OzadaliK, IrannejadH, EmamiS. Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and beta-amyloid aggregation inhibitors. Arch. Pharm.348(3), 179–187 (2015).
  • Tai WT , LuT, YuanHLet al. Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors. J. Mol. Model18(7), 3087–3100 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.